United States-based Avet Pharmaceuticals Inc. announced on Thursday that it has launched its Propofol Injectable Emulsion, USP 10mg/mL, in 20, 50 and 100ml Single Patient-Use Vials, an AB rated generic equivalent of DIPRIVAN(R) (propofol) Injectable Emulsion USP, in the United States.
The product has been launched subsequent to its abbreviated new drug application approval from the United States Food and Drug Administration (FDA). It is an intravenous general anaesthetic and sedation drug. The product is a trademark of Fresenius Kabi USA, LLC.
Avet Pharmaceuticals said that it will start distribution of the product immediately.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US